Benzinga  Sep 26  Comment 
In a report published Thursday, Leerink Swann analyst Marko Kozul upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Market Perform to Outperform, and raised the price target from $57.00 to $76.00. In the report, Leerink Swann...
StreetInsider.com  Aug 6  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Trius+Therapeutics%2C+Inc.+%28TSRX%29+Posts+Q2+Loss+of+41cShare/8572326.html for the full story.
StreetInsider.com  Jul 31  Comment 
Jive Software (NASDAQ: JIVE) 18% LOWER; reported Q2 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $35.16 million. Jive Software sees Q3 2013 EPS...
Benzinga  Jul 31  Comment 
Questcor Pharmaceuticals (NASDAQ: QCOR) moved up 18.47% to $61.50 in the pre-market session after the company reported upbeat Q2 earnings. Trius Therapeutics (NASDAQ: TSRX) soared 17.25% to $13.73 in the pre-market trading after the company...
New York Times  Jul 31  Comment 
After Cubist Pharmaceuticals announced it would buy Trius Therapeutics and Optimer Pharmaceuticals to strengthen its antibiotics portfolio, its shares rose in after-hours trading.     
StreetInsider.com  Jul 30  Comment 
Jive Software (NASDAQ: JIVE) 17% LOWER; reported Q2 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $35.16 million. Jive Software sees Q3 2013 EPS...
Benzinga  Jul 30  Comment 
After the close Tuesday, Cubist Pharmaceuticals (NASDAQ: CBST) announced its intention to acquire two separate companies, Trius Therapeutics (NASDAQ: TSRX) and Optimer Pharmaceuticals (NASDAQ: OPTR) for a combined total potential value of $1.619...
FierceBiotech  Jul 30  Comment 
Cubist Pharmaceuticals surprised some analysts with the announcements of two major acquisitions Tuesday afternoon, agreeing to buy both Trius Therapeutics and Optimer Pharmaceuticals to build its antibiotics business. The combined deal values $1.6...
Reuters  Jul 30  Comment 
Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.
Benzinga  Jul 12  Comment 
Shares of Trius Therapeutics (NASDAQ: TSRX) rose 9.5% Thursday and another 2% after-hours, as Jim Cramer interviewed the company's CEO Jeff Stein. Trius' drug Tedizolid has completed the phase 3 clinical trial for the treatment of acute...


Trius Therapeutics (NASDAQ:TSRX): develops and sells antibiotics to combat life-threatening infectious diseases. The company's most advanced drug is entering Phase 3 of clinical trials, which is the final phase.[1] The company predicts that the market for drugs of this caliber is approximately $1.4B. Trius only has one identified competitor in the space with a drug that is already released. However, the Trius's drug is expected to be safer, more effective, and more powerful.[2]

The company plans to continue to expand and develop other antibiotics both independently and through partnerships with other organizations. Trius Therapeutics also competes for government contracts and funding which support the research and discovery of antibiotic compounds.[3] In the past, the company has generated over a $1M in revenue solely from collaborations and grants.[4]

The company's initial public offering of stock is filed on the NASDAQ and went public on August 2nd, 2010. Its initial price range was $12-$14, but the company priced far below the range at $5. To make up for this drop in price, the company raised its offer from 6M shares to 10M, making the deal approximately worth $50M. The lead underwriters of the deal are Citigroup (C) and Piper Jaffray Companies (PJC).[5] The company's IPO is expected to be used to increase funding for operations and to help maintain its $57.5M accumulated deficit.[4]

For FY2009 with year ended 31 December 2009, the company reported total revenues of $5 million, a large increase from $1.33 million in total revenue for FY2008. However, the company had a net loss of $22 million for FY2009, a substantial increase from the $9 million net loss recorded for FY2008. [4]


  1. National Marrow Donor Program "What Is a Clinical Trial?"
  2. TSRX S-1 2010 "Prospectus Summary" pg 1-2
  3. TSRX S-1 2010 "Our Strategy" pg 4
  4. 4.0 4.1 4.2 TSRX S-1A 2010 "Summary Financial Data" pg 9
  5. Renaissance IPO - Trius Therapeutics
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki